Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;36(3):325-337.
doi: 10.14670/HH-18-295. Epub 2020 Dec 23.

Implications of androgen receptor and FUS expression on tumor progression in urothelial carcinoma

Nermine Mohamed Abd Raboh  1 , Sarah Adel Hakim  2 , Rasha Mohamed Abd El Atti  2
Affiliations

Implications of androgen receptor and FUS expression on tumor progression in urothelial carcinoma

Nermine Mohamed Abd Raboh et al. Histol Histopathol. 2021 Mar.

Abstract

Androgen receptor (AR) interact with many pathways involved in bladder cancer development and progression. FUS (fused in liposarcoma), a multifunctional protein essential for different cellular processes, has been demonstrated as a key link between androgen receptor signaling and cell-cycle progression in prostate cancer but has not been examined in urothelial carcinoma (UC) despite an intimate association between prostate and bladder carcinogenesis.

Aim: To examine the immunohistochemical expression of AR and FUS in urothelial carcinoma in relation to prognostic parameters and to extrapolate any possible link between the expression of both markers and tumor progression.

Study design: Retrospective study using immunohistochemical staining for AR and FUS on (88) cases of urothelial carcinoma.

Results: AR shows statistically significant relations with late tumor stage, high tumor grade, and non-papillary tumor pattern. On the other hand, FUS expression correlates with early tumor stage, low tumor grade and papillary pattern. An inverse relation is found between AR and FUS expression (p=0.001). Cases with high AR IHC expression show statistically significant shorter OS, RFS and PFS compared to cases with low AR expression. Cases with high FUS IHC expression reveal statistically significant longer OS, RFS and PFS compared to cases with low FUS expression.

Conclusion: FUS expression is associated with favorable prognostic parameters of UC. A possible interaction is suggested between FUS and AR pathways involved in urothelial cancer progression. Manipulating FUS levels and androgen deprivation therapy can provide new promising targets for treatment trials.

PubMed Disclaimer

References

    1. Amin M.B., Edge S., Greene F., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C., Jessup J.M., Brierley J.D., Gaspar L.E., Schilsky R.L., Balch C.M., Winchester D.P., Asare E.A., Madera M., Gress D.M. and Meyer. L.R (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J. Clin. 67, 93-99. - PubMed
    1. Boorjian S., Ugras S., Mongan N.P., Gudas L.J., You X., Tickoo S.K. and Scherr D.S (2004). Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64, 383-388. - PubMed
    1. Boorjian S.A., Heemers H.V., Frank I., Farmer S.A., Schmidt L.J., Sebo T.J. and Tindall D.J (2009). Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr. Relat. Cancer 16, 123-137. - PMC - PubMed
    1. Brooke G.N., Culley R.L., Dart D.A., Mann D.J., Gaughan L., McCracken S.R., Robson C.N., Spencer-Dene B., Gamble S.C., Powell S.M., Wait R., Waxman J., Walker M.M. and Bevan C.L. (2011). FUS/TLS is a novel mediator of androgen-dependent cellcycle progression and prostate cancer growth. Cancer Res. 71, 914- 924. - PubMed
    1. Chen J., Cui Y., Li P., Liu L., Li C.H. and Xiongbing Z.U (2017). Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis. Mol. Clin. Oncol. 7, 919-927. - PMC - PubMed

MeSH terms

Grants and funding